Quest Diagnostics said its 2025 Annual Meeting of Stockholders was held on May 15, 2025, and that the director nominees listed in the filing were elected for terms expiring at the 2026 Annual Meeting of Stockholders.

1. 01

   Quest Diagnostics said its 2025 Annual Meeting of Stockholders was held on May 15, 2025, and that the director nominees listed in the filing were elected for terms expiring at the 2026 Annual Meeting of Stockholders.

2. 02

   The company said director nominee Robert B. Carter received 94,240,720 votes for, 298,067 against and 262,706 abstentions, and James E. Davis received 86,900,389 votes for and 7,692,258 against.

3. 03

   Quest Diagnostics said the advisory resolution on executive officer compensation was approved with 85,922,577 votes for and 8,570,674 against, and the appointment of PricewaterhouseCoopers as independent auditor for 2025 was approved with 95,585,333 votes for and 6,869,657 against.

4. 04

   The company said a stockholder proposal on calling a special meeting of stockholders was not approved, with 9,480,355 votes for, 84,410,956 against and 910,175 abstentions.

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.